. 2024 May 9;15:1391562. doi: 10.3389/fphar.2024.1391562

TABLE 1.

Clinical trials of ICIs in adjuvant setting.

Trial	Patients	Agent (target)	Phase, arm	Study design	Size	Primary endpoint
ATTRACTION-5 (NCT03006705)	-	Nivolumab (PD-1)	III, two-arm	Nivolumab + S-1/CAPOX	377	3-year RFS	68.4%
ATTRACTION-5 (NCT03006705)	-	Nivolumab (PD-1)	III, two-arm	Placebo + S-1/CAPOX	378	3-year RFS	65.3%
JUPITER-15 (NCT05180734)	-	Toripalimab (PD-1)	III, two-arm	Toripalimab + SOX/XELOX	340	DFS
JUPITER-15 (NCT05180734)	-	Toripalimab (PD-1)	III, two-arm	Placebo + SOX/XELOX	340	DFS
NCT05184946	-	Camrelizumab (PD-1)	II, two-arm	Camrelizumab + SOX	36	3-year DFS
NCT05184946	-	Camrelizumab (PD-1)	II, two-arm	SOX only	36	3-year DFS
NCT05468138	dMMR/MSI-H	Sintilimab/Nivolumab (PD-1)	II/III, three-arm	Sintilimab/Nivolumab only	141	3-year DFS
				SOX/XELOX only
				observation
NCT05769725	PD-L1CPS≥5/EBV+/dMMR/MSI-H	Serplulimab (PD-1)	II, two-arm	Serplulimab + DS	35	1-year DFS
NCT05769725	PD-L1CPS≥5/EBV+/dMMR/MSI-H	Serplulimab (PD-1)	II, two-arm	DS only	35	1-year DFS
NCT04997837	D2/R0 resected with pN3	multiple PD-1 inhibitors	III, two-arm	PD-1+CRT	433	3-year DFS
NCT04997837	D2/R0 resected with pN3	multiple PD-1 inhibitors	III, two-arm	Chemotherapy	433	3-year DFS

CAPOX: Capecitabine + Oxaliplatin; XELOX: Xeloda + Oxaliplatin; SOX: S-1 + Oxaliplatin; DS: Docetaxel + S-1; CRT: chemoradiotherapy; RFS: recurrence free survival; DFS: disease free survival.